
FDA approves olanzapine, a once-monthly subcutaneous injection for adults with schizophrenia, boosting symptom control while reducing monitoring needs and highlighting weight risks.
Implementing these assessments, interventions, and mobile apps could contribute to improved disease detection, treatment strategies, and adherence.
Recent cystic fibrosis (CF) research reports have introduced a variety of new practice tools-assessments, interventions, and mobile apps-that could contribute to improved patient care in the areas of disease detection, treatment strategies, and adherence. Scroll through the slides below to find concise summaries of key points.






